

Cases from the Community: Integrating New Research Findings into Practice

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following any-grade adverse events (AEs) was most commonly reported with ifinatamab deruxtecan for patients with previously treated extensive-stage small cell lung cancer in the Phase II IDEate-Lung01 study?**
 - Interstitial lung disease
 - Nausea**
 - Pulmonary embolism
 - QT interval prolongation
- 2. Luspatercept promotes red blood cell maturation by binding to members of which of the following protein superfamilies?**
 - GPCR
 - Immunoglobulin
 - TGF- β**
 - Thrombospondin
- 3. Which of the following statements best describes the incidence of febrile neutropenia observed with the addition of quizartinib versus placebo to induction and consolidation chemotherapy and continued as a single agent for patients with newly diagnosed acute myeloid leukemia with a FLT3-ITD mutation in the Phase III QuANTUM-First trial?**
 - Incidence of febrile neutropenia was significantly reduced for patients receiving quizartinib
 - Incidence of febrile neutropenia was similar between the study arms**
 - Incidence of febrile neutropenia was 50% higher for patients receiving quizartinib
- 4. In the Phase II IMbark trial, imetelstat demonstrated clinically meaningful outcomes in which of the following populations of patients with myelofibrosis?**
 - Patients whose disease is treatment naïve
 - Patients whose disease is relapsed/refractory to JAK inhibition**
 - Patients whose disease is heavily pretreated (after 4 or more prior lines of therapy)
 - Patients with platelet counts below 50,000/ μ L
- 5. Which of the following proteins is targeted by the antibody-drug conjugate raludotatug deruxtecan, under investigation for the management of ovarian cancer?**
 - AKT
 - TROP2
 - CDH6**
 - NTRK
- 6. Which of the following outcomes best reflects overall survival (OS) with tisotumab vedotin in comparison to investigator's choice of chemotherapy as second- or third-line therapy for recurrent cervical cancer in the Phase III innovaTV 301 trial?**
 - No improvement in OS
 - A numerical but nonsignificant trend toward improved OS
 - A significant improvement in OS**

Cases from the Community: Integrating New Research Findings into Practice

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

7. Results from the Phase III RUBY trial suggest a progression-free survival (PFS) benefit with dostarlimab and carboplatin/paclitaxel for patients with which of the following subsets of primary advanced or recurrent endometrial cancer?
- Mismatch repair-proficient/microsatellite-stable disease
 - Mismatch repair-deficient/microsatellite instability-high disease
 - Both a and b
 - Neither a nor b
8. Results of the Phase II DESTINY-PanTumor02 trial suggest that trastuzumab deruxtecan (T-DXd) has meaningful clinical activity in which of the following subsets of biliary tract cancer?
- Disease with a HER2 mutation
 - HER2-low (IHC 1+ or 2+) disease
 - HER2-overexpressing (IHC 3+) disease
 - All of the above
 - Only b and c
9. Which of the following adverse events is most frequently observed with TAS-102?
- Diarrhea
 - Fatigue
 - Neutropenia
 - Hypertension
10. Which of the following outcomes was significantly improved with T-DXd for patients with previously treated HER2-positive advanced gastric cancer in the Phase II DESTINY-Gastric01 trial?
- PFS
 - PFS and OS
 - Neither PFS nor OS